Julian Baker’s BioAtla BCAB Stock Holding History

Julian Baker’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-16,500	Closed	-$2.35M	–	116
2022 Q2	$2.35M	Hold	16,500	–	–	0.01%	94
2022 Q1	$4.13M	Hold	16,500	–	–	0.02%	90
2021 Q4	$16.2M	Hold	16,500	–	–	0.08%	63
2021 Q3	$24.3M	Hold	16,500	–	–	0.11%	56
2021 Q2	$35M	Hold	16,500	–	–	0.15%	49
2021 Q1	$41.9M	Hold	16,500	–	–	0.18%	47
2020 Q4	$28.1M	Buy	+16,500	New	+$27.6M	0.11%	48

Other funds holding BCAB

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Julian Baker's BCAB Position: Q3 2022 in Review

Julian Baker sold out of BioAtla (BCAB) in Q3 2022, closing a stake of 16,500 shares — an estimated $2.35M sold.

Julian Baker first reported a position in BCAB in Q4 2020 and held it in 7 quarters. The position peaked at $41.9M in Q1 2021. 73 funds tracked by Wall St. Rank hold BCAB as of Q3 2022.

Julian Baker reported no remaining BioAtla position as of Q3 2022 after selling out during the quarter.
Julian Baker sold 16,500 BioAtla shares in Q3 2022, an estimated $2.35M.
Julian Baker first reported a position in BioAtla in Q4 2020 and held it in 7 quarters.
Julian Baker's BioAtla position peaked at $41.9M in Q1 2021.
73 funds tracked by Wall St. Rank held BioAtla as of Q3 2022.

Based on Baker Bros. Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.